Alvotech (ALVO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Alvotech Stock (ALVO) Company Profile

Healthcare (1165)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ALVO's Discussions on Twitter

Vergleichen Sie ALVO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALVO Alvotech	9.30	2.83B	391.87M	-441.45M	-301.21M	-1.85
ZTS Zoetis Inc	163.26	72.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	14.96	47.08B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.15	45.99B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.32	17.38B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.87	14.05B	612.78M	-86.37M	-62.91M	-0.87

Alvotech Stock (ALVO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-14	Eingeleitet	UBS	Buy
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2023-10-20	Hochstufung	Citigroup	Sell → Neutral
2023-09-21	Eingeleitet	Barclays	Equal Weight
2022-09-07	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-06	Herabstufung	Citigroup	Buy → Sell
2022-07-26	Eingeleitet	Citigroup	Buy

Alle ansehen

Alvotech Aktie (ALVO) Neueste Nachrichten

Finanzdaten der Alvotech-Aktie (ALVO)

Alvotech (ALVO)

Alvotech Stock (ALVO) Company Profile

Vergleichen Sie ALVO mit anderen Aktien

Alvotech Stock (ALVO) Upgrades & Downgrades

Alvotech Aktie (ALVO) Neueste Nachrichten

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs - insights.citeline.com

Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year - Center for Biosimilars®

Oaktree Capital Management LP Sells 606,322 Shares of Alvotech (NASDAQ:ALVO) - MarketBeat

Alvotech (NASDAQ:ALVO) Issues Earnings Results - MarketBeat

Alvotech (NASDAQ:ALVO) Stock Price Down 7.6%Time to Sell? - MarketBeat

Alvotech (NASDAQ:ALVO) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance

Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge By Investing.com - Investing.com Australia

Aurion names Arnaud Lacoste CEO - BioCentury

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024 - insights.citeline.com

Alvotech Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Alvotech Achieves Record Revenue Growth in 2024 - TipRanks

Earnings call transcript: Alvotech’s Q4 2024 results show revenue surge - Investing.com India

Trump Must Be ‘Harsh’ With Big Pharma, Says Icelandic Drugmaker - Bloomberg.com

Alvotech Appoints Dr. Balaji V. Prasad As Chief Strategy Officer - MarketScreener

Alvotech Appoints New Chief Strategy Officer to Strengthen Market Position - TipRanks

Alvotech Achieves Record 2024 Financial Results and Expands Biosimilar Pipeline - TipRanks

Iceland's Alvotech Appoints Chief Strategy Officer - MarketScreener

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - The Manila Times

Alvotech earnings missed by $0.04, revenue topped estimates - Investing.com Australia

Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView

Alvotech earnings missed by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Alvotech : Press Release Full Year 2024 - MarketScreener

Alvotech Reports Record Results for 2024 and Provides Business Update - The Manila Times

Alvotech Shatters Growth Records: 427% Revenue Surge Signals Major Biosimilar Breakthrough - Stock Titan

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - insights.citeline.com

Alvotech And Advanz Make First Omalizumab Filing - Citeline News & Insights

Alvotech SA MHRA Accepts Marketing Application For AVT23 Biosimilar To Xolair - Marketscreener.com

Alvotech’s Biosimilar to Xolair Gains UK Regulatory Acceptance - TipRanks

Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair - MarketScreener

UK Medicines and Healthcare Products Regulatory - GlobeNewswire

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - The Manila Times

Earnings Scheduled For March 26, 2025 - Benzinga

UK Medicines and Healthcare Products Regulatory Agency - GlobeNewswire

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewswire Inc.

Royce & Associates LP Raises Stock Holdings in Alvotech (NASDAQ:ALVO) - MarketBeat

Alvotech, Partners Say UK Regulator Accepted Market Application for Proposed Xolair Biosimilar - Marketscreener.com

FDA accepts Teva, Alvotech BLAs for Simponi biosimilars - MSN

Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat

Short Interest in Alvotech (NASDAQ:ALVO) Expands By 21.7% - MarketBeat

Alvotech acquires Xbrane’s R&D operations in Sweden and biosimilar candidate XB003 - MSN

FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars - Drug Store News

Northland reiterates Alvotech stock with $28 target on acquisition By Investing.com - Investing.com Canada

Alvotech Acquires Xbrane's R&D Operations, Expanding Biosimilars Development Capabilities - Nasdaq

Northland reiterates Alvotech stock with $28 target on acquisition - Investing.com India

Icelandic Biotech Company Alvotech to Explore Listing in Stockholm - MarketWatch

Alvotech and Dr. Reddy’s gets FDA nod for Biologic License Application for AVT03 - MSN

Alvotech Snaps Up Xbrane’s R&D And Cimzia Rival For $27m - insights.citeline.com

Alvotech Expands with Acquisition of Xbrane’s R&D Operations - TipRanks

Finanzdaten der Alvotech-Aktie (ALVO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ALVO